The evolving landscape of diabetes care is seeing a significant shift, driven by novel incretin-based therapies. Currently, semaglutide has secured considerable attention, but rival medications like tirzepatide, https://keziatcgu268414.pointblog.net/the-future-of-diabetes-comparing-tirzepatide-semaglutide-retatrutide-and-cagrilintide-93267407